關於康友
ddd

         Pharmally International Holding Company Limited (hereinafter ‘Pharmally’) was established in 2013 with the registered capital of TWD1 billion. The current share capital of Pharmally is TWD0.68 billion and the number of employees is about 1,200. Luan Worldbest Pharmaceutical Company Limited (hereinafter ‘Luan Worldbest’), the wholly-own subsidiary of Pharmally, is the production base of Pharmally, with an area of 300 acres. Luan Worldbest focuses on the production and development of Large Volume Parental (LVP) and Active Pharmaceutical Ingredient (API), and currently owns 10 production lines of LVP, 2 production workshops for API, product approval for 9 kinds of APIs and 55 kinds of LVPs. The annual production capacity of Luan Worldbest: bottle LVP of 250 million bottles/year, polypropylene LVP of 195 million bottles/year, soft bag LVP(Non-PVC co-extruded film bags) of 185 million bags/year, Nikethamide of 300 tons/year, and Levofloxacin Lactate of 160 tons/year.

         At present, the company is actively involved in the production of animal vaccines, cooperating with Harbin Weike Biotechnology Development Company, which owns the most advanced bird flu vaccine technology in the world, to set up a poultry vaccine manufacturing enterprise in Indonesia, so as to expand its growth. By expanding overseas, the company will diversify its pharmaceutical products, from the production of human pharmaceuticals to the production of animal vaccines. It will also speed up the internationalization strategy of Pharmally, extending the market from China to Indonesia and even Asean.

        With the business philosophy of caring for life, diligence and dedication, Pharmally set up a group of top professional team, through its own production technology, to provide safe and effective high-quality products, build business reputation and lay a foundation for sustainable development.
          In order to enhance the competitive advantage of the Company, Pharmally cooperated with famous academic research institutes to adopt the first domestic new technology to implement the technological transformation of dextran API. While expanding the production capacity, the quality of the products is also higher than the national pharmacopoeia standards and occupy the leading position in the country.
       "Credit first, safe and effective", is our commitment to customers, Pharmally invested heavily in setting up advanced quality control laboratories and importing sophisticated detection equipment. Sticking to strict international quality standards, Pharmally produces high-quality drugs to meet people's health need. 

          Regarding the quality as lifeline, Pharmally followed the most stringent standards of operation from the construction of the plant to the production process control. We strictly monitor air, water and power to create a zero-pollution production environment. Through the first-class production equipment, the Company improved efficiency significantly, realized clean production, reduced environmental protection costs, and implemented safety responsibility system and standardized on-site management, to effectively control operation quality. 

         With the promotion of the new rural cooperative medical policy, the demand for LVPs and APIs will continue to grow. Meanwhile, Pharmally, which is located in the three major agricultural provinces in the Mainland China, will continue to strengthen its production technology, introduce more advanced production equipment, and expand its production capacity and scale. It is hoped that through our efforts, we will guard people's health and create a better future.





  • The intersection of East Gaocheng Road & Jingliu Rd.,ETDA,Lu'an,Anhui Province,China
  • Tel:(86)564-3698-859
  • Contact:Mr. Zhang
  • Cel.:(886)965-262-958
  • Email:zhangyj@pharmally.com
  • Taipei Office Address:
  • Room 1807, No.333, Sec.1, Keelung Rd., Xinyi Dist, Taipei,11012,Taiwan(R.O.C)
  • Tel:(886)02-2757-6000
  • Fax:(886)02-2757-6111
  • Email:tw@pharmally.com